Non-Interventional Study on the Tolerability and Efficacy of IVIG

NCT02303093 · clinicaltrials.gov ↗

COMPLETED

Status

344

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary and Secondary Immunodeficiency and Other Conditions Requiring Regular Administration of Octagam 5% or 10% IVIG

Interventions

BIOLOGICAL: Octagam IVIG 5% or 10%
BIOLOGICAL: Panzyga

Sponsor

Octapharma